Hope in stopping melanoma from spreading: Study shows that inhibiting key protein prevents metastasis to lungs in mice

March 5, 2013
An image of Melanoma skin cancer. Credit: Courtesy of University of Utah Health Care

(Medical Xpress)—Researchers have identified a critical protein role in the metastasis of melanoma, the most serious form of skin cancer. Inhibition of the protein known as adenosine diphosphate ribosylation factor 6 (ARF6) reduces the spread of melanoma to the lungs in mice, according to a study published in the March 5 issue of Science Signaling online, suggesting that targeting ARF6 may be an effective approach to preventing melanoma metastasis.

Melanoma is the sixth most common cancer in the United States. Approximately one in 50 people will develop melanoma in their lifetime, and the number of melanoma cases diagnosed each year is increasing faster than for any other cancer. While melanoma generally starts as a single , cancer cells can spread, or metastasize, to distant sites throughout the body such as the liver, lungs, and brain.

"Metastasis is what makes melanoma lethal, but our knowledge of how melanoma spreads is limited," says Allie Grossmann, M.D., Ph.D., molecular genetic pathology fellow at the University of Utah and co-first author on the study. "By improving our understanding of the responsible for melanoma metastasis, we can better identify targeted therapies that may stop the spread of ."

Although significant progress has been made in the treatment of metastatic melanoma, currently available treatments still can't achieve long-term survivorship in most patients. Grossmann and her colleagues discovered a new molecular pathway involving ARF6 that promotes metastasis and can be inhibited by a small molecule known as SecinH3. "The surprising discovery that SecinH3 seems to inhibit the entire metastatic signaling cascade represents a potential breakthrough that may lead to improvements in the efficacy of current drug therapy. Our findings are exciting because the clinical implications extend beyond melanoma to other cancers, such as and a type of known as glioblastoma, in which invasion is also mediated by ARF6."

Based on the findings of this study and other previous studies by the same group that show the importance of ARF6 in other biological processes, Navigen Inc., a Salt Lake City-based pharmaceutical and medical device company, is investigating new ARF6 inhibitors for pre-clinical studies.

"Although SecinH3 itself is not suitable for treatment in human patients, it serves as a useful model compound for demonstrating that small-molecule inhibitors of ARF6 may have therapeutic value in melanoma," says Shannon Odelberg, Ph.D., U of U assistant professor of internal medicine and neurobiology and anatomy Navigen scientist, and a contributing author on the study. "Our findings are the first step toward developing potent therapies that may actually prevent or reduce melanoma metastasis," says Odelberg, also part of the Molecular Medicine Program at the University of Utah. "These new therapies could potentially be used in combination with current drugs to produce a more effective treatment for melanoma."

Explore further: Gene inactivation drives spread of melanoma: study

Related Stories

Gene inactivation drives spread of melanoma: study

June 11, 2012
Why do some cancers spread rapidly to other organs and others don't metastasize? A team of UNC researchers led by Norman Sharpless, MD, have identified a key genetic switch that determines whether melanoma, a lethal skin ...

Research breakthrough could halt melanoma metastasis

November 14, 2012
In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 ...

Researchers identify key role of microRNAs in melanoma metastasis

July 11, 2011
Researchers at the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, identified for the first time the key role specific microRNAs (miRNAs) play in melanoma metastasis to simultaneously ...

Fighting melanoma's attraction to the brain

September 19, 2012
(Medical Xpress)—The process of metastasis, by which cancer cells travel from a tumor site and proliferate at other sites in the body, is a serious threat to cancer patients. According to the National Cancer Institute, ...

P Rex-1 protein key to melanoma metastasis

November 22, 2011
Researchers from UNC Lineberger Comprehensive Cancer Center are part of a team that has identified a protein, called P-Rex1, that is key to the movement of cells called melanoblasts. When these cells experience uncontrolled ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.